• 1
    Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, Herrero JI, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38:811817.
  • 2
    Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M, David MF, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end- stage liver disease. Hepatology 1994; 19:612.
  • 3
    Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207210.
  • 4
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424432.
  • 5
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847.
  • 6
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687696.
  • 7
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.Lamivudine Transplant Group. Hepatology 1999; 29:15811586.
  • 8
    Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002; 22(Suppl 1):2332.
  • 9
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808816.
  • 10
    Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718723.
  • 11
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134.
  • 12
    Peters M, Hann H, Martin P, Heathcote E, Buggisch P, Moorat A, Sullivan M, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (lam) suppresses lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis [Abstract}. J Hepatol 2001: 36(Suppl 31): A13.
  • 13
    Schiff ER, Lai C-L, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, et al. Adefovir dipivixil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:14191427.
  • 14
    Richman DD. Drug resistance and its implications in the management of HIV infection. Antiviral Therapy 1997; 2(Suppl 4):4158.
  • 15
    Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181:12211233.
  • 16
    Mutimer D, Pillay D, Cook P, Ratcliffe D, O'Donnell K, Dowling D, Shaw J, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181:713716.
  • 17
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292297.
  • 18
    Villeneuve J, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (in press).
  • 19
    Xiong S, Yang H, Westland C, Delaney IW, Colledge D, Bartholomeusz A, Thibault V, et al. Resistance surveillance of HBeAg- chronic hepatitis B patients treated for two years with adefovir dipivoxil [Abstract]. J Hepatol 2003: 38(Suppl):A4543.
  • 20
    Zoulim F. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models. Antivir Chem Chemother 2001; 12:131142.
  • 21
    Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003; 38:545553.
  • 22
    Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710722.
  • 23
    Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12(Suppl 1):119129.
  • 24
    Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:13511359.
  • 25
    Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7:161165.
  • 26
    Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46:25252532.